Trial Profile
A Phase I Dose Escalation Study of NKP-1339 Administered on Days 1, 8 and 15 of Each 28-Day Cycle in Patients With Advanced Solid Tumors Refractory to Treatment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs BOLD 100 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Niiki Pharma
- 19 Jun 2013 Status changed from active, no longer recruiting to completed, based on information in an Intezyne Technologies media release.
- 02 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jan 2012 Interim results of the first 30 patients evaluable for dose determination have been presented in a media release from Niiki Pharma.